Inhibition of human immunodeficiency virus 1 protease in vitro: rational design of substrate analogue inhibitors
about
Pathogenesis of human immunodeficiency virus infectionDesign, Synthesis, and Biological Evaluation of Potent Quinoline and Pyrroloquinoline Ammosamide Analogues as Inhibitors of Quinone Reductase 2X-ray crystallographic structure of a complex between a synthetic protease of human immunodeficiency virus 1 and a substrate-based hydroxyethylamine inhibitorHuman immunodeficiency virus type 1 protease inhibitors irreversibly block infectivity of purified virions from chronically infected cellsPotent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating eventStructure-based design of nonpeptide inhibitors specific for the human immunodeficiency virus 1 proteaseIn vitro anti-human immunodeficiency virus (HIV) activity of XM323, a novel HIV protease inhibitorCGP 53437, an orally bioavailable inhibitor of human immunodeficiency virus type 1 protease with potent antiviral activityIn vitro isolation and identification of human immunodeficiency virus (HIV) variants with reduced sensitivity to C-2 symmetrical inhibitors of HIV type 1 proteaseAntiretroviral activities of protease inhibitors against murine leukemia virus and simian immunodeficiency virus in tissue cultureInhibition of multiple phases of human immunodeficiency virus type 1 replication by a dithiane compound that attacks the conserved zinc fingers of retroviral nucleocapsid proteinsGenetic selection of poliovirus 2Apro-binding peptidesStructure-based drug design approaches for predicting binding affinities of HIV1 protease inhibitors.beta-Galactosidase containing a human immunodeficiency virus protease cleavage site is cleaved and inactivated by human immunodeficiency virus proteaseComparison of the HIV-1 and HIV-2 proteinases using oligopeptide substrates representing cleavage sites in Gag and Gag-Pol polyproteins.Antiretroviral therapy: strategies beyond single-agent reverse transcriptase inhibition.Strategies in the treatment of AIDS and related diseases: the lessons of cancer chemotherapy.The Continuing Evolution of HIV-1 Therapy: Identification and Development of Novel Antiretroviral Agents Targeting Viral and Cellular Targets.Effect of retroviral proteinase inhibitors on Mason-Pfizer monkey virus maturation and transmembrane glycoprotein cleavageIdentification of HIV inhibitors guided by free energy perturbation calculations.Mutational analysis of a native substrate of the human immunodeficiency virus type 1 proteinaseHIV-1 protease as a potential target for anti-AIDS therapy.Reduced-bond tight-binding inhibitors of HIV-1 protease. Fine tuning of the enzyme subsite specificity.Kinetics of antiviral activity and intracellular pharmacokinetics of human immunodeficiency virus type 1 protease inhibitors in tissue culture.A time-of-drug addition approach to target identification of antiviral compounds.Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: virus fitness in the absence and in the presence of drug.Mutagenesis of protease cleavage sites in the human immunodeficiency virus type 1 gag polyprotein.Expression of active human immunodeficiency virus type 1 protease by noninfectious chimeric virus particles.Solvent accessibility as a predictive tool for the free energy of inhibitor binding to the HIV-1 protease.Model peptides to study the effects of P2 and P3 substitutions in statine-containing HIV proteinase inhibitors.Pseudo-symmetrical difluoroketones. Highly potent and specific inhibitors of HIV-1 protease.Anti-retroviral strategies for AIDS and related diseases.Synergistic binding of inhibitors to the protease from HIV type 1.Pentacycloundecane-diol-based HIV-1 protease inhibitors: biological screening, 2D NMR, and molecular simulation studies.
P2860
Q24634681-7F359634-AF2C-4EE8-A549-7935C2FD315CQ27676483-3CAB39A6-77D1-4633-9A38-EF328C078AF8Q27678325-E0768B3E-CA48-4549-83F0-9CDDC8EB3B4EQ28318483-07E95265-3A5E-4FF9-9D5A-3BF91BBFAB91Q28320362-E1B5EE4A-DFA4-49F5-9AB0-30BD364B6A98Q28331230-B94AA7DE-22AB-406F-9D05-CE9621C2A7E6Q28369528-60FDE4ED-FDCA-4FDD-AFA0-A39B445DBDD9Q28378396-10FBE449-1CE6-4E5F-B63D-8DF101D775D2Q28378566-57DDFB5D-C5CD-4364-BF08-2CAB0F588F0EQ28378612-6AA7A9BA-FBD8-40CB-B322-DBA0985646A9Q28379468-1A68BAFB-4BFC-4E72-AFE9-5894EF7B1746Q31957787-8E765D33-9A3F-4989-9116-E010AE2C9AF6Q33751567-7BF12543-6ECB-487B-B892-2F95D0C3D35DQ33927954-94D5A870-02F9-43DC-812D-826F781ED8BBQ34098983-1B2A6EC9-9645-457F-B099-F815F9632F12Q35325810-A7651BBD-F965-49A6-997C-67E274BFAEE0Q35930774-1D4AEC3C-91B4-4F84-8D1B-C1BE34856426Q36104509-31CC9A34-0BCD-480C-A35F-6B75716AAEDBQ36698832-378623C7-DC64-41F2-A379-BE98B6B5C762Q36708826-4645F4E5-0CDD-4AE8-8518-796285F4E533Q36812551-CC04E26E-8EF8-4A07-9E93-ABB7DC9E11A0Q37783047-7336E1C7-646A-4B58-8FD0-0B66344F4557Q39237086-65102727-DEB3-441C-9ED6-420AB0562465Q39472141-BB64D8E1-E390-43C1-A685-A3093312D60FQ39531429-4718F91E-BFB8-4427-8153-FB300ED95F9BQ39612306-7D89644A-EC6D-4641-9C17-6F16C18D2C7BQ40059062-C6EE6C1A-3478-4BB4-9CAF-96FC104062EDQ40064802-13CD25D1-8730-4D39-B0A7-CE2DFE549983Q41816295-A681E67F-E81B-460F-8DD8-06CFF18CCF57Q42288166-EDD69FC6-0F5D-4E3B-96E5-57236E388CB9Q42288265-F5EFA4E0-38E6-4077-844F-9DF519443AE3Q42543077-A9996A55-C811-4765-80E0-1314BB68FE30Q42981548-6FE668BF-3955-4229-9169-DBE4F661DB35Q45264671-35EE07D9-ABA3-4B27-9606-272F4B79C6DF
P2860
Inhibition of human immunodeficiency virus 1 protease in vitro: rational design of substrate analogue inhibitors
description
1989 nî lūn-bûn
@nan
1989 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1989 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
name
Inhibition of human immunodefi ...... substrate analogue inhibitors
@ast
Inhibition of human immunodefi ...... substrate analogue inhibitors
@en
Inhibition of human immunodefi ...... substrate analogue inhibitors
@nl
type
label
Inhibition of human immunodefi ...... substrate analogue inhibitors
@ast
Inhibition of human immunodefi ...... substrate analogue inhibitors
@en
Inhibition of human immunodefi ...... substrate analogue inhibitors
@nl
prefLabel
Inhibition of human immunodefi ...... substrate analogue inhibitors
@ast
Inhibition of human immunodefi ...... substrate analogue inhibitors
@en
Inhibition of human immunodefi ...... substrate analogue inhibitors
@nl
P2093
P2860
P356
P1476
Inhibition of human immunodefi ...... substrate analogue inhibitors
@en
P2093
A C Chandler
B W Metcalf
G B Dreyer
J E Strickler
S A Fakhoury
T A Tomaszek
V W Magaard
P2860
P304
P356
10.1073/PNAS.86.24.9752
P407
P577
1989-12-01T00:00:00Z